When Paxlovid Is “Commercialized” In 2023, Patient Access To The Covid-19 Treatment Will Depend On Insurance Status

Regardless of what happens to Paxlovid's price once the drug is commercialized in 2023, a uniquely American situation will emerge in which a person ’s access to a potentially life-saving Covid-19 treatment will likely depend on arbitrary features like insurance status, age, and Medicaid-eligibility.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Tags: Healthcare /healthcare Innovation /innovation business pharma & Source Type: news